Phase IIa Randomized Placebo Controlled Clinical Study of Codivir in Hospitalized Patients with Moderate COVID-19
Condition: COVID-19 · Sponsor: Code Pharma
About this study
This is a double-blind, multicentre, multinational study to evaluate the safety and collect preliminary efficacy data of Codivir drug product in 130 hospitalized adults with moderate COVID-19 symptoms. COVID-19 symptoms (fever, cough, myalgia and changes in smell or taste) onset must be within 7 days prior enrolment. Treatment will begin in the hospital, participants will be discharged according to medical decision and continue the treatment until to Day 7 at home and followed up to day 28.
This description comes directly from the study's public registry record.
Talk to the study team
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
Locations (5)
| Hospital de Amor | Paulo Prata, Barretos/SP/BRA, Brazil | Recruiting |
| Infection Control | Prado, Belo Horizonte/MG/BRA, Brazil | Recruiting |
| Instituto Lobus | Casa de Pedra, Volta Redonda/RJ/BRA, Brazil | Recruiting |
| A2Z Clinical | Vila Martina, Volta Redonda/RJ/BRA, Brazil | Recruiting |
| Casa de Saude | Centro, Brazil | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05218356